20 results on '"Wang Rong"'
Search Results
2. Survival benefits of para-aortic lymphadenectomy in colorectal cancer with clinically suspected para-aortic lymph node metastasis: a meta-analysis and systematic review
- Author
-
Wang, Rong-Chang, Wang, Jian-Qi, Zhou, Xiao-Yu, Zhong, Chu-lin, Chen, Jin-Xu, and Chen, Jing-Song
- Published
- 2023
- Full Text
- View/download PDF
3. miR-125-5p inhibits thyroid cancer growth and metastasis by suppressing the ERK/PI3K/AKT signal pathway
- Author
-
Wang, Rong, Wang, Chen, Meng, Xian-Jie, and Wei, Li
- Published
- 2021
- Full Text
- View/download PDF
4. Overexpression of osteopontin promotes cell proliferation and migration in human nasopharyngeal carcinoma and is associated with poor prognosis
- Author
-
Qin, Haimei, Wang, Rong, Wei, Guijiang, Wang, Huaifei, Pan, Guogang, Hu, Rentong, Wei, Yesheng, Tang, Renguang, and Wang, Junli
- Published
- 2017
- Full Text
- View/download PDF
5. Correction: ScRNA-seq revealed an immunosuppression state and tumor microenvironment heterogeneity related to lymph node metastasis in prostate cancer.
- Author
-
Xin, Shiyong, Liu, Xiang, Li, Ziyao, Sun, Xianchao, Wang, Rong, Zhang, Zhenhua, Feng, Xinwei, Jin, Liang, Li, Weiyi, Tang, Chaozhi, Mei, Wangli, Cao, Qiong, Wang, Haojie, Zhang, Jianguo, Feng, Lijin, and Ye, Lin
- Subjects
LYMPHATIC metastasis ,TUMOR microenvironment ,METASTASIS ,IMMUNOSUPPRESSION ,PROSTATE cancer ,HETEROGENEITY - Abstract
This document is a correction notice for an article titled "ScRNA-seq revealed an immunosuppression state and tumor microenvironment heterogeneity related to lymph node metastasis in prostate cancer" published in Experimental Hematology & Oncology. The correction addresses an error in Fig. 3E, F of the article, where the authors mistakenly used the wrong picture. The correct figure is provided in the correction notice. The original article has been corrected. The publisher, Springer Nature, remains neutral regarding jurisdictional claims and institutional affiliations. [Extracted from the article]
- Published
- 2024
- Full Text
- View/download PDF
6. Characteristics and response to next‐generation sequencing‐guided therapy in locally advanced or metastatic esophageal cancer.
- Author
-
Ma, Yueyun, Li, Wenjie, Chen, Shiyu, Lin, Shuimiao, Ding, Sijie, Zhou, Xiaomei, Liu, Tongxin, Wang, Rong, and Wang, Wei
- Subjects
ESOPHAGEAL cancer ,METASTASIS ,PROGNOSIS ,NUCLEOTIDE sequencing ,PROGRESSION-free survival ,OVERALL survival - Abstract
Esophageal cancer (EC) is a main cause of cancer‐related deaths. However, genomic alterations and the clinical value of next‐generation sequencing (NGS) in advanced or metastatic EC for precision therapy remain largely unclear. Herein, we performed comprehensive analyses on a cohort of 47 individuals with advanced or metastatic EC who underwent NGS between May 2017 and February 2020. Eventually, 227 mutated genes were identified in the cohort. TP53, NQO1, DPYD, GSTM1, XRCC1 and ERCC1 were the most mutated genes and associated with immune cell infiltration, autophagy and hypoxia. Patients who received NGS‐guided treatments exhibited better objective remission rate (ORR) (72.22%), disease control rate (DCR) (88.89%), overall survival (OS) (P =.0019) and progression‐free survival (PFS) (P =.0077) than those not receiving NGS‐guided therapies. The multivariate analyses further demonstrated that the NGS‐guided therapy was an independently prognostic factor (OS: hazard radio [HR] 0.31, 95% coincidence interval [CI] 0.1‐0.97, P =.04). In conclusion, we depicted a comprehensive mutational landscape of 47 patients with locally advanced or metastatic EC and illustrated the utility of NGS testing to guide clinical management in improving ORR, DCR, OS and PFS. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
7. miR-129-3p, as a diagnostic and prognostic biomarker for renal cell carcinoma, attenuates cell migration and invasion via downregulating multiple metastasis-related genes
- Author
-
Chen, Xuanyu, Ruan, Anming, Wang, Xuegang, Han, Weiwei, Wang, Rong, Lou, Ning, Ruan, Hailong, Qiu, Bin, Yang, Hongmei, and Zhang, Xiaoping
- Published
- 2014
- Full Text
- View/download PDF
8. MiR‐205‐5p promotes lung cancer progression and is valuable for the diagnosis of lung cancer.
- Author
-
Zhao, Yu‐Long, Zhang, Jia‐Xiang, Yang, Juan‐Juan, Wei, Yu‐Bo, Peng, Jie‐Fei, Fu, Chang‐Jin, Huang, Min‐Hua, Wang, Rong, Wang, Ping‐Yu, Sun, Guang‐Bin, and Xie, Shu‐Yang
- Subjects
DISEASE progression ,REVERSE transcriptase polymerase chain reaction ,FLOW cytometry ,CELL culture ,CANCER invasiveness ,LUNG tumors ,MICRORNA ,METASTASIS ,GENE expression ,IMMUNOBLOTTING ,CELL survival ,CELL proliferation ,GENES ,TUMOR markers ,POLYMERASE chain reaction ,RECEIVER operating characteristic curves - Abstract
Background: MicroRNAs (miRNAs) function as potential diagnostic biomarkers in various cancers. This study aimed to evaluate the roles of miR‐205‐5p in lung cancer progression and diagnosis. Materials and Methods: MiR‐205‐5p was detected by quantitative real‐time PCR. The effect of miR‐205‐5p on cell proliferation and metastasis was estimated by MTT and flow cytometry. The expression of TP53INP1 and related genes was analyzed by immunoblotting. The diagnostic value of miR‐205‐5p was analyzed using receiver operating characteristic (ROC) curve analysis, sensitivity, and specificity. Results: The miR‐205‐5p was increased in lung cancer tissues. MiR‐205‐5p mimics were promoted but its inhibitor suppressed cell proliferation and metastasis compared with control treatment in vitro and in vivo. By regulating the 3′ untranslated region, miR‐205‐5p could negatively regulate TP53INP1 expression, which further inhibited the expression of RB1 and P21, but increased that of cyclinD1. Moreover, the serum miR‐205‐5p levels of patients with lung cancer were significantly higher than those of normal controls, and they were correlated with patients' gender, drinking status, and clinical stage. The area under the ROC curve of serum miR‐205‐5p in the diagnosis of non‐small‐cell lung cancer was 0.8250, respectively. The finding supported its possession of high diagnostic efficiency for lung cancer. Conclusions: MiR‐205‐5p promoted lung cancer cell proliferation and metastasis by negatively regulating the novel target TP53INP1, which further affected the expression of P21, RB1, and cyclin D1. Serum miR‐205‐5p is a novel and valuable biomarker for lung cancer diagnosis. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
9. Donafenib in Progressive Locally Advanced or Metastatic Radioactive Iodine-Refractory Differentiated Thyroid Cancer: Results of a Randomized, Multicenter Phase II Trial.
- Author
-
Lin, Yan-Song, Yang, Hui, Ding, Yong, Cheng, Yi-Zhuang, Shi, Feng, Tan, Jian, Deng, Zhi-Yong, Chen, Zhen-Dong, Wang, Rong-Fu, Ji, Qing-Hai, Huang, Rui, and Li, Lin-Fa
- Subjects
THYROID cancer ,HAND-foot syndrome ,ADVERSE health care events ,METASTASIS ,PROGRESSION-free survival ,KINASE inhibitors - Abstract
Background: An unmet need for more effective and affordable kinase inhibitors remains in patients with progressive radioactive iodine-refractory differentiated thyroid cancer (RAIR-DTC) in China, where only sorafenib is approved for this indication. This study evaluated the 24-week objective response rate (ORR) to donafenib—a new, domestic multikinase inhibitor—in the treatment of locally advanced or metastatic RAIR-DTC in patients with measurable lesions. Two dose regimens (300 mg twice daily vs. 200 mg twice daily) were used to determine its optimal dosage and safety for further phase III studies. Methods: This study was a randomized, open-label, multicenter phase II trial. Thirty-five adult RAIR-DTC patients with at least one measurable targeted lesion according to RECIST 1.1 were enrolled from 12 centers in China and randomized to receive either 200 mg (17 patients) or 300 mg (18 patients) of donafenib orally twice daily for 24 weeks. The primary endpoint was ORR, and the secondary endpoints included progression-free survival (PFS) among others. Additionally, biochemical (serum thyroglobulin) and structural (total tumor diameter [TTD]) responses were assessed, change (ΔTTD) rates were calculated, and safety was evaluated. Results: The ORRs for the 200- and 300-mg arms were 12.5% and 13.33% (p = 1.000), respectively. The 300-mg arm had a nonsignificant, longer median PFS than the 200-mg arm (14.98 months vs. 9.44 months) (p = 0.351). There was a trend toward more tumor shrinkage in the 300-mg arm compared with the 200-mg arm (average ΔTTD rate −0.52 ± 0.71 vs. −0.04 ± 1.55 mm/month, p = 0.103). Most treatment-related adverse events (AEs) in both arms were grades 1–2. The most common grade 3 treatment-related AEs in both arms were palmar–plantar erythrodysesthesia and hypertension; the sum occurrence rates of these two AEs in the 200-mg and 300-mg arms were 11.43% and 22.86%, respectively. Conclusions: Donafenib was generally well tolerated. Both donafenib regimens demonstrated similar efficacy in terms of the ORR in locally advanced or metastatic RAIR-DTC. The results warrant further studies on donafenib as a new, feasible treatment option for RAIR-DTC patients. Clinical Trials.gov IDs: NCT02870569; CTR20160220. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
10. Molecular basis of V-ATPase inhibition by bafilomycin A1.
- Author
-
Wang, Rong, Wang, Jin, Hassan, Abdirahman, Lee, Chia-Hsueh, Xie, Xiao-Song, and Li, Xiaochun
- Subjects
ADENOSINE triphosphatase ,MACROLIDE antibiotics ,CELL communication ,METASTASIS ,SEQUENCE analysis ,AUTOPHAGY ,CLARITHROMYCIN - Abstract
Pharmacological inhibition of vacuolar-type H
+ -ATPase (V-ATPase) by its specific inhibitor can abrogate tumor metastasis, prevent autophagy, and reduce cellular signaling responses. Bafilomycin A1, a member of macrolide antibiotics and an autophagy inhibitor, serves as a specific and potent V-ATPases inhibitor. Although there are many V-ATPase structures reported, the molecular basis of specific inhibitors on V-ATPase remains unknown. Here, we report the cryo-EM structure of bafilomycin A1 bound intact bovine V-ATPase at an overall resolution of 3.6-Å. The structure reveals six bafilomycin A1 molecules bound to the c-ring. One bafilomycin A1 molecule engages with two c subunits and disrupts the interactions between the c-ring and subunit a, thereby preventing proton translocation. Structural and sequence analyses demonstrate that the bafilomycin A1-binding residues are conserved in yeast and mammalian species and the 7'-hydroxyl group of bafilomycin A1 acts as a unique feature recognized by subunit c. Bafilomycin A1, a member of macrolide antibiotics and an autophagy inhibitor, serves as a specific and potent V-ATPases inhibitor. Here authors report the cryo-EM structure of bafilomycin A1-bound V-ATPase with six bafilomycin A1 molecules bound to the c-ring and reveal the molecular basis for Bafilomycin A1 inhibition of the V-ATPase. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
11. Cryo-EM structures of intact V-ATPase from bovine brain.
- Author
-
Wang, Rong, Long, Tao, Hassan, Abdirahman, Wang, Jin, Sun, Yingyuan, Xie, Xiao-Song, and Li, Xiaochun
- Subjects
ADENOSINE triphosphatase ,INTRACELLULAR membranes ,MEMBRANE proteins ,CELL membranes ,METASTASIS ,HETERODIMERS - Abstract
The vacuolar-type H
+ -ATPases (V-ATPase) hydrolyze ATP to pump protons across the plasma or intracellular membrane, secreting acids to the lumen or acidifying intracellular compartments. It has been implicated in tumor metastasis, renal tubular acidosis, and osteoporosis. Here, we report two cryo-EM structures of the intact V-ATPase from bovine brain with all the subunits including the subunit H, which is essential for ATPase activity. Two type-I transmembrane proteins, Ac45 and (pro)renin receptor, along with subunit c", constitute the core of the c-ring. Three different conformations of A/B heterodimers suggest a mechanism for ATP hydrolysis that triggers a rotation of subunits DF, inducing spinning of subunit d with respect to the entire c-ring. Moreover, many lipid molecules have been observed in the Vo domain to mediate the interactions between subunit c, c", (pro)renin receptor, and Ac45. These two structures reveal unique features of mammalian V-ATPase and suggest a mechanism of V1-Vo torque transmission. The vacuolar-type H+ -ATPases (V-ATPase) hydrolyze ATP to pump protons across the plasma or intracellular membrane. Here authors report two cryo-EM structures of the intact V-ATPase from bovine brain with all the subunits including the subunit H, which is essential for ATPase activity. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
12. Overexpression of CD155 relates to metastasis and invasion in osteosarcoma.
- Author
-
Zhuo, Baobiao, Li, Yuan, Gu, Feng, Li, Zhengwei, Sun, Qingzeng, Shi, Yingchun, Shen, Yang, Zhang, Fengfei, Wang, Rong, and Wang, Xiaodong
- Subjects
OSTEOSARCOMA ,METASTASIS ,GENETIC overexpression ,CANCER invasiveness ,FOCAL adhesion kinase - Abstract
The rapid development of metastatic lesions remains the leading cause of mortality for patients with osteosarcoma. CD155 serves a key role in cancer cell migration, invasion and metastasis. However, the function and mechanism of CD155 has not been explored in osteosarcoma metastasis. In the present study, we found that CD155 was significantly upregulated in lung metastatic tissue and the highly metastatic cell line K7M2-WT (K7M2) of osteosarcoma. Overexpression of CD155 in K7M2 cells enhanced lung metastasis, while inhibition of CD155 by an anti-CD155 monoclonal antibody reduced metastasis. Blocking of CD155 also decreased migration and invasion of K7M2 cells in vitro. A western blot analysis revealed that blocking of CD155 inhibits metastasis by downregulating focal adhesion kinase (FAK) and phosphorylated FAK (pFAK) in osteosarcoma. The results revealed that CD155 serves a crucial role in the metastasis of osteosarcoma by regulating FAK and may provide a novel molecular target for therapeutic intervention in metastatic osteosarcoma. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
13. Overexpression of osteopontin promotes cell proliferation and migration in human nasopharyngeal carcinoma and is associated with poor prognosis.
- Author
-
Qin, Haimei, Wang, Rong, Wei, Guijiang, Wang, Huaifei, Pan, Guogang, Hu, Rentong, Wei, Yesheng, Tang, Renguang, and Wang, Junli
- Subjects
- *
OSTEOPONTIN , *CELL proliferation , *METASTASIS , *THERAPEUTICS - Abstract
Nasopharyngeal carcinoma (NPC), a malignant tumor at the top and side of the nasopharyngeal cavity, highly occurs in the southern region of China. Cancer cell metastasis is one of the leading causes of death in NPC patients. Osteopontin (OPN), is a phosphorylated extracellular matrix protein with a variety of functions, was found to be overexpressed in many cancers. However, the expression and role of OPN in patients with NPC in Guangxi, China are unclear. Here, we observed that NPC patients had upregulated OPN at mRNA protein and levels. Immunochemistry (IHC) analysis of OPN expression in 68 NPC clinical specimens indicated that high expression of OPN had positive correlation with NPC lymph node metastasis (
P = 0.012), distant metastasis (P = 0.001) and TNM staging (P = 0.018). Moreover, compared with relatively low OPN, NPC patients with higher expression of OPN showed a poorer overall survival rate (P = 0.001, log rank test). Multivariate analysis showed that OPN expression in NPC was an independent prognostic marker. The proliferation, apoptosis and migration ability of CEN-2Z cancer cells in NPC were determined by MTT, flow cytometry and wound-healing assays, respectively. Upregulation of OPN in CEN-2Z cancer cells promoted cancer cell proliferation and migration, and suppressed apoptosis. In sum, our result suggests OPN could be used as a valuable oncoprotein and show that overexpression of OPN in NPC may serve as a potential prognostic marker. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
14. Disruption of the c-Myc/miR-200b-3p/PRDX2 regulatory loop enhances tumor metastasis and chemotherapeutic resistance in colorectal cancer.
- Author
-
Zhenbing Lv, Jinlai Wei, Wenxian You, Rong Wang, Jingkun Shang, Yongfu Xiong, Hua Yang, Xuanhua Yang, Zhongxue Fu, Lv, Zhenbing, Wei, Jinlai, You, Wenxian, Wang, Rong, Shang, Jingkun, Xiong, Yongfu, Yang, Hua, Yang, Xuanhua, and Fu, Zhongxue
- Subjects
COLON cancer treatment ,METASTASIS ,CANCER chemotherapy ,PEROXIREDOXINS ,POLYMERASE chain reaction ,POST-translational modification - Abstract
Background: Metastasis is a major threat to colorectal cancer (CRC) patients. We have reported that peroxiredoxin-2 (PRDX2) is associated with CRC invasion and metastasis. However, the mechanisms regulating PRDX2 expression remain unclear. We investigate whether microRNAs (miRNAs) regulate PRDX2 expression in CRC progression.Methods: Quantitative real-time polymerase chain reaction (qPCR) was used to measure microRNA-200b-3p (miR-200b-3p) expression. Immunohistochemistry (IHC) was performed to detect c-Myc and PRDX2 protein levels in CRC tissue samples (n = 97). Western blot was used to quantify PRDX2, c-Myc, AKT2/GSK3β pathway-associated proteins and epithelial-mesenchymal transition (EMT)-related proteins in CRC cells. Luciferase reporter assays were used to analyze the interaction between miR-200b-3p and 3'untranslated region (3'UTR) of PRDX2 mRNA and AKT2 mRNA as well as c-Myc and the miR-200b-3p promoter. Chromatin immunoprecipitation (ChIP) assay was used to evaluate binding of c-Myc to the miR-200b-3p promoter. Invasive assay and metastatic model were used to assess invasive and metastatic capacities of CRC cells in vitro and in vivo. Moreover, drug-induced apoptosis was measured by flow cytometry.Results: We found that miR-200b-3p was significantly downregulated, whereas c-Myc and PRDX2 were upregulated in metastatic CRC cells and CRC tissues compared to their counterparts. An inverse correlation existed between c-Myc and miR-200b-3p, and between miR-200b-3p and PRDX2. We also found that PRDX2 was a target of miR-200b-3p. Importantly, overexpression of nontargetable PRDX2 eliminated the suppressive effects of miR-200b-3p on proliferation, invasion, EMT, chemotherapeutic resistance and metastasis of CRC cells. Moreover, c-Myc bound to the promoter of miR-200b-3p and repressed its transcription. In turn, miR-200b-3p disrupted the stability of c-Myc protein by inducing c-Myc protein threonine 58 (T58) phosphorylation and serine 62 (S62) dephosphorylation via AKT2/GSK3β pathway.Conclusions: Our findings reveal that the c-Myc/miR-200b/PRDX2 loop regulates CRC progression and its disruption enhances tumor metastasis and chemotherapeutic resistance in CRC. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
15. In vivo imaging xenograft models for the evaluation of anti-brain tumor efficacy of targeted drugs.
- Author
-
Kita, Kenji, Arai, Sachiko, Nishiyama, Akihiro, Taniguchi, Hirokazu, Fukuda, Koji, Wang, Rong, Yamada, Tadaaki, Takeuchi, Shinji, Tange, Shoichiro, Tajima, Atsushi, Nakada, Mitsutoshi, Yasumoto, Kazuo, Motoo, Yoshiharu, Murakami, Takashi, and Yano, Seiji
- Subjects
TARGETED drug delivery ,XENOGRAFTS ,BRAIN tumor treatment ,ONCOGENES ,CRIZOTINIB ,CANCER treatment ,METASTASIS ,GENE fusion ,THERAPEUTICS - Abstract
Molecular-targeted drugs are generally effective against tumors containing driver oncogenes, such as EGFR, ALK, and NTRK1. However, patients harboring these oncogenes frequently experience a progression of brain metastases during treatment. Here, we present an in vivo imaging model for brain tumors using human cancer cell lines, including the EGFR-L858R/T790M-positive H1975 lung adenocarcinoma cells, the NUGC4 hepatocyte growth factor ( HGF)-dependent gastric cancer cells, and the KM12 SM colorectal cancer cells containing the TPM3- NTRK1 gene fusion. We investigated the efficacy of targeted drugs by comparison with their effect in extracranial models. In vitro, H1975 cells were sensitive to the third-generation epidermal growth factor receptor inhibitor osimertinib. Moreover, HGF stimulated the proliferation of NUGC4 cells, that was inhibited by crizotinib, which has anti- MET activity. KM12 SM cells were sensitive to the tropomyosin-related kinase-A inhibitors crizotinib and entrectinib. In in vivo H1975 cell models, osimertinib inhibited the progression of both brain and subcutaneous tumors. Furthermore, in in vivo NUGC4 cell models, crizotinib remarkably delayed the progression of brain tumors, and that of peritoneal carcinomatosis. Interestingly, in in vivo KM12 SM cell models, treatment with crizotinib delayed the progression of liver metastases, but not that of brain tumors. Conversely, treatment with entrectinib discernibly delayed the progression of both tumor types. Thus, the effect of targeted drugs against brain tumors can differ from the one reported in extracranial tumors. Moreover, the same multikinase inhibitory drug can display different efficacies in brain tumor models containing different drivers. Therefore, our in vivo imaging model for brain tumors may prove useful for preclinical drug screening against brain metastases. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
16. Long non-coding RNA MIAT promotes gastric cancer proliferation and metastasis via modulating the miR-331-3p/RAB5B pathway.
- Author
-
Li, Xiao-Mei, Jiao, Yan-Yan, Luan, Bao-Hong, Wu, Hong-Xia, Wang, Rong-Rong, and Zhong, Jie
- Subjects
NON-coding RNA ,STOMACH cancer ,METASTASIS ,APOPTOSIS ,MESSENGER RNA - Abstract
Gastric cancer (GC) remains a threat to the health of the global population. The present study investigated the effects and mechanisms of the long non-coding RNA myocardial infarction associated transcript (MIAT) on the proliferation, apoptosis and metastasis of GC (HGC-27 and AGS) cells. The expression levels of MIAT, micoRNA (miR)-331-3p and RAB5B mRNA were analyzed using reverse transcription-quantitative PCR analysis. Cell growth, apoptosis, migration and invasion were measured using 5-ethynyl-2′-deoxyuridine, flow cytometry, wound healing and Transwell assays, respectively. A luciferase assay was used to determine whether miR-331-3p targeted MIAT and RAB5B. The results indicated that MIAT levels were significantly upregulated in GC tissues and cells, correlated with RAB5B levels and inversely associated with miR-331-3p levels. MIAT overexpression promoted proliferation and metastasis, and inhibited the apoptosis of GC cells. MIAT knockdown had the opposite effect on GC cells. The rescue experiments revealed that the effects of MIAT knockdown on the biological behaviour of GC cells were attenuated by RAB5B overexpression. These data suggest that MIAT promotes GC progression via modulating miR-331-3p/RAB5B pathway. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
17. miRNA-381-3p Functions as a Tumor Suppressor to Inhibit Gastric Cancer by Targeting Fibroblast Growth Factor Receptor-2.
- Author
-
Gao, Xiang, Liu, Huiqi, Wu, Qiong, Wang, Rong, Huang, Mingyu, Ma, Qiang, and Liu, Yongnian
- Subjects
- *
STOMACH tumors , *FIBROBLAST growth factors , *FLOW cytometry , *CANCER invasiveness , *MICRORNA , *CELL receptors , *APOPTOSIS , *METASTASIS , *GENE expression , *CELL motility , *TUMOR suppressor genes , *TISSUES , *RESEARCH funding , *CELL proliferation , *CELL lines , *POLYMERASE chain reaction - Abstract
Objectives: MicroRNAs possess essential effects on gastric cancer (GC), whereas the underlying mechanisms have not been fully uncovered. The present work focused on investigating the role of miR-381-3p in GC cellular processes and the possible mechanisms. Materials and Methods: miR-381-3p levels within GC tissues and cells were measured through quantitative real-time polymerase chain reaction (qRT-PCR). This study measured cell proliferation, apoptosis, and metastasis through EdU, colony formation, flow cytometry, and Transwell assays separately. TargetScan was adopted to predict the miR-381-3p targets, whereas luciferase reporter assay was adopted for confirmation. Results: miR-381-3p levels were decreased, whereas fibroblast growth factor receptor-2 (FGFR2) expression was increased in GC. miR-381-3p upregulation inhibited proliferation, migration, and invasion and it promoted the apoptosis of GC cells. Further, FGFR2 overexpression partly reversed the miR-381-3p-mediated impacts on GC cellular processes. Conclusions: This study provides an experimental basis, suggesting the potential of using miR-381-3p as the novel marker for GC. Clinical Trial Registration number: 2020-05. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
18. Doublecortin-like kinase 1 is a novel biomarker for prognosis and regulates growth and metastasis in basal-like breast cancer.
- Author
-
Lv, Yuetao, Song, Ge, Wang, Rong, Di, Linlin, and Wang, Jianling
- Subjects
- *
CORTIN , *BIOMARKERS , *BREAST cancer prognosis , *GENETIC overexpression , *MESSENGER RNA - Abstract
Doublecortin like kinase 1 (DCLK1) was observed overexpressed in several types of human cancers, and played a functional role in tumorigenicity, but little is known about the biological function of DCLK1 in basal-like breast cancer. In our results, the expressions of DCLK1 mRNA and protein were elevated in basal-like breast cancer tissues and cell lines. DCLK1 high-expression associated with clinical stage, lymph node metastasis, distant metastasis and histological grade. DCLK1 high-expression was an independent unfavorable prognostic factor for basal-like breast cancer patients. The biological experiments suggested knockdown of DCLK1 induced inhibition of basal-like breast cancer cells proliferation, migration and invasion. In conclusion, DCLK1 serves as a prognostic biomarker for basal-like breast cancer and a potential therapeutic target for basal-like breast cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
19. BPA exposure enhances the metastatic aggression of ovarian cancer through the ERα/AKT/mTOR/HIF-1α signaling axis.
- Author
-
Xie, Xin, Zhu, Yan, Cheng, Huimin, Li, Haili, Zhang, Yadi, Wang, Rong, Li, Wenyong, and Wu, Fengrui
- Subjects
- *
OVARIAN cancer , *METASTASIS , *LACTIC acid , *CARBON metabolism , *MASS spectrometry - Abstract
Long-term exposure to bisphenol A (BPA) in humans may promote ovarian cancer development. In present study, the mechanisms by which BPA mediates the aggression metastatic behavior of ovarian cancer were investigated in vitro/in vivo. The results showed that BPA (10 μM) significantly promoted the proliferation, migration and invasion of human ovarian cancer cells (ES-2 and OVCAR-3 cells); moreover, it promoted ES-2 and OVCAR-3 cell glucose uptake, lactic acid release and intracellular ATP synthesis. After administration of 5 μg/kg/day BPA, tumor volume was increased compared with that in control group. KEGG and GO enrichment analyses showed that the genes from ES-2 cell in 10 μM BPA-treated group were enriched mainly in central carbon metabolism and PI3K-AKT signaling pathway. Then, qRT‒PCR and western blotting results showed that BPA (10 μM) increased the mRNA and protein expression levels of glycolysis-related genes and mTOR, p-AKT HIF-1α and ERα in vitro/vivo ; whereas this effect was reduced after treatment with the ERα inhibitor methyl-piperidino-pyrazole. Furthermore, coimmunoprecipitation and mass spectrometry showed that BPA promoted the direct interaction of ERα with lactate dehydrogenase A. These results show that BPA directly promoted the proliferation, migration and invasion of ovarian cancer cells through the ERα/AKT/mTOR/HIF-1α signaling axis to enhance glycolysis. • BPA promoted the proliferation, migration and invasion of human ovarian cancer cells. • BPA promoted glucose uptake, lactic acid release and ATP synthesis in tumor cells. • Glycolysis was promoted by the ERα/AKT/mTOR/HIF-1α signaling axis after BPA exposure. • BPA facilitated the interaction between ERα and LDHA in ovarian cancer cells. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
20. Effects of synthetic glucocorticoids on breast cancer progression.
- Author
-
Pang, Jia Meng, Huang, Yi-Chen, Sun, Shu-Pin, Pan, Yan-Ru, Shen, Chia-Yi, Kao, Ming-Chien, Wang, Rong-Hsuan, Wang, Lu-Hai, and Lin, Kai-Ti
- Subjects
- *
METASTATIC breast cancer , *CANCER invasiveness , *CANCER cell growth , *BREAST cancer , *STEROID receptors , *METASTASIS - Abstract
• Low-dose GCs suppress breast tumor growth and metastases in two breast cancer xenograft mouse models. • High-dose GCs enhance breast tumor growth and metastases in two breast cancer xenograft mouse models. • DEX suppress cell adhesion, migration, and invasion in a dose-dependent manner in multiple breast cancer cell lines. Glucocorticoids (GCs) are widely prescribed as adjuvant therapy for breast cancer patients. Unlike other steroid hormone receptors, the GC receptor is not considered an oncogene. Research in the past few years has revealed the complexity of GC-mediated signaling, but it remains puzzling whether GCs promote or inhibit tumor progression in different cancer types. Here we evaluated the potential of using a synthetic GC, dexamethasone (DEX), in the treatment of breast cancer. We found that the administration of low-dose DEX suppressed tumor growth and distant metastasis in the MCF-7 and MDA-MB-231 xenograft mouse model, whereas treatment with high-dose DEX enhanced tumor growth and metastasis, respectively. Treatment of breast cancer cells with DEX inhibited cell adhesion, migration, and invasion in a dose-dependent manner. The DEX-mediated inhibition of cell adhesion, migration, and invasion is partly through induction of microRNA-708 and subsequent Rap1B-mediated signaling in MDA-MB-231 cells. On the other hand, in MCF-7 cells, DEX-suppressed cell migration is independent from microRNA-708 mediated signaling. Overall, our data reveal that DEX acts as a double-edged sword during breast-cancer progression and metastasis: Lower concentrations inhibit breast cancer tumor growth and metastasis, whereas higher concentrations may play an undesired role to promote breast cancer progression. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.